Silencing of the UCHL1 gene in giant cell tumors of bone

International Journal of Cancer

Volumn 127, Issue 8, 2010, Pages 1804-1812

  Fellenberg, Jörg ^a   Lehner, Burkhard ^a   Witte, Daniela ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

DNA methylation; giant cell tumor; mesenchymal stem cells; mRNA expression; silencing; UCHL1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; UBIQUITIN CARBOXY TERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; MESSENGER RNA; TUMOR MARKER; UCHL1 PROTEIN, HUMAN;

ADULT; ARTICLE; BONE MARROW CELL; BONE TUMOR; CLINICAL ARTICLE; COMPARATIVE STUDY; CPG ISLAND; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GIANT CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MESENCHYMAL STEM CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; STROMA CELL; CELL CULTURE; CELL PROLIFERATION; DNA METHYLATION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; BONE NEOPLASMS; CELL PROLIFERATION; CELLS, CULTURED; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; GIANT CELL TUMORS; HUMANS; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

EID: 77956987105     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25205     Document Type: Article

References (40)

1. Wulling M, Engels C, Jesse N, Werner M, Delling G, Kaiser E,. The nature of giant cell tumor of bone. J Cancer Res Clin Oncol 2001; 127: 467-74.
2. Zheng MH, Robbins P, Xu J, Huang L, Wood DJ, Papadimitriou JM,. The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 2001; 16: 297-307.
3. Osaka S, Toriyama M, Taira K, Sano S, Saotome K,. Analysis of giant cell tumor of bone with pulmonary metastases. Clin Orthop Relat Res 1997; 335: 253-61.
4. Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Sollazzo MR, Merli M, Ferrari C, Magagnoli G, Bertoni F, Picci P,. Prognostic relevance of C-myc gene expression in giant-cell tumor of bone. J Orthop Res 1998; 16: 1-7.
5. Burmester GR, Winchester RJ, Dimitriu-Bona A, Klein M, Steiner G, Sissons HA,. Delineation of four cell types comprising the giant cell tumor of bone. Expression of Ia and monocyte-macrophage lineage antigens. J Clin Invest 1983; 71: 1633-48.
6. Goldring SR, Schiller AL, Mankin HJ, Dayer JM, Krane SM,. Characterization of cells from human giant cell tumors of bone. Clin Orthop Relat Res 1986; 204: 59-75.
7. Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM,. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000; 15: 640-9.
8. Robinson D, Einhorn TA,. Giant cell tumor of bone: a unique paradigm of stromal-hematopoietic cellular interactions. J Cell Biochem 1994; 55: 300-303.
9. James IE, Dodds RA, Olivera DL, Nuttall ME, Gowen M,. Human osteoclastoma-derived stromal cells: correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo. J Bone Miner Res 1996; 11: 1453-60.
10. Joyner CJ, Quinn JM, Triffitt JT, Owen ME, Athanasou NA,. Phenotypic characterisation of mononuclear and multinucleated cells of giant cell tumour of bone. Bone Miner 1992; 16: 37-48.
11. Wulling M, Delling G, Kaiser E,. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol 2003; 34: 983-93.
12. Robinson D, Segal M, Nevo Z,. Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis. Pathobiology 2002; 70: 333-42.
13. Jones PA, Baylin SB,. The epigenomics of cancer. Cell 2007; 128: 683-92.
14. Esteller M,. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007; 16 Spec No 1: R50-9.
15. Baylin SB, Herman JG,. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-74.
16. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, Ushijima T,. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 2006; 119: 1338-44.
17. Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun DI, Xiao Y, Hoque MO, Westra WH, Califano JA, Sidransky D,. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 2004; 64: 5982-7.
18. Yu J, Tao Q, Cheung KF, Jin H, Poon FF, Wang X, Li H, Cheng YY, Rocken C, Ebert MP, Chan AT, Sung JJ,. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology 2008; 48: 508-18.
19. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH, Goggins M,. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003; 63: 3735-42.
20. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J,. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989; 246: 670-3.
21. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT, Jr,. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002; 111: 209-18.
22. Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, Sato Y, Nishikawa K, Sun YJ, Sakurai M, Harada T, Hara Y, et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 2003; 12: 1945-58.
23. Haynesworth SE, Baber MA, Caplan AI,. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 1992; 13: 69-80.
24. Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM,. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001; 98: 2615-25.
25. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-21.
26. Mann DA, Trowern AR, Lavender FL, Whittaker PA, Thompson RJ,. Identification of evolutionary conserved regulatory sequences in the 5? untranscribed region of the neural-specific ubiquitin C-terminal hydrolase (PGP9.5) gene. J Neurochem 1996; 66: 35-46.
27. Huang L, Teng XY, Cheng YY, Lee KM, Kumta SM,. Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. Bone 2004; 34: 393-401.
28. Murata A, Fujita T, Kawahara N, Tsuchiya H, Tomita K,. Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci 2005; 10: 581-8.
29. Werner M,. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop 2006; 30: 484-9.
30. Gamberi G, Benassi MS, Ragazzini P, Pazzaglia L, Ponticelli F, Ferrari C, Balladelli A, Mercuri M, Gigli M, Bertoni F, Picci P,. Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone. Ann Oncol 2004; 15: 498-503.
31. Wuelling M, Delling G, Kaiser E,. Differential gene expression in stromal cells of human giant cell tumor of bone. Virchows Arch 2004; 445: 621-30.
32. Pricola KL, Kuhn NZ, Haleem-Smith H, Song Y, Tuan RS,. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem 2009; 108: 577-88.
33. Tezel E, Hibi K, Nagasaka T, Nakao A,. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000; 6: 4764-7.
34. Takase T, Hibi K, Yamazaki T, Nakayama H, Taguchi M, Kasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A,. PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterology 2003; 50: 1278-80.
35. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A,. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 2002; 8: 192-5.
36. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002; 8: 2298-305.
37. Mizukami H, Shirahata A, Goto T, Sakata M, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K,. PGP9.5 methylation as a marker for metastatic colorectal cancer. Anticancer Res 2008; 28: 2697-700.
38. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, Carvalho AL, Jiang WW, Park HL, Kim MS, Osada M, Mori M, et al. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005; 65: 4963-8.
39. Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, Mori M, Sidransky D,. The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer 2008; 123: 753-9.
40. Mani A, Gelmann EP,. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23: 4776-89.